Jena, January 31th 2018 – oncgnostics GmbH partners with the MEDIREX Group. MEDIREX thus holds the exclusive rights for marketing the test for early and reliable detection of cervical cancer, […]
Jena, April 5th, 2017: The Chinese pharma company Changchun Jienuo Medical Technology (CJMT), a subsidiary of the Chinese state-owned SINOPHARM Group (www.sinopharm.com/en), has purchased an exclusive license from oncgnostics (www.oncgnostics.com) […]
Jena, November 9th, 2016 – The biotech company oncgnostics (www.oncgnostics.com) will present its new version of the triage test GynTect – a test for the fast and reliable detection of […]
Jena, September 20th, 2016 – GynTect, a molecular diagnostic test developed by the biotech company oncgnostics, allows fast and reliable diagnostics of cervical cancer and the corresponding precancerous stages. The […]
Those who have once been suspected to suffer from a severe disease know all-too-well, how long and grueling it can be to wait for further examinations that might bring clarity. […]
Bangalore/Jena, 28.04.2016 – The biotech firm oncgnostics GmbH will start distributing its molecular diagnostic test GynTect for use in cervical cancer diagnostics in an exclusive partnership with Sayre Therapeutics. GynTect […]
Jena / Frickenhausen, January 20th, 2016 – With the start of 2016 the distribution of the cervical cancer triage test GynTect® by Greiner Bio-One has started. For this purpose the […]
Jena (Germany), September 18th, 2015 – A new test for use in cervical cancer screening is CE-IVD marked in whole Europe with immediate effect. It may quickly yield reliable test […]